RT Journal Article
T1 European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain.
A1 Caldas, María
A1 Pérez-Aisa, Ángeles
A1 Castro-Fernández, Manuel
A1 Bujanda, Luis
A1 Lucendo, Alfredo J
A1 Rodrigo, Luis
A1 Huguet, Jose M
A1 Pérez-Lasala, Jorge
A1 Molina-Infante, Javier
A1 Barrio, Jesús
A1 Fernández-Salazar, Luis
A1 Lanas, Ángel
A1 Perona, Mónica
A1 Domínguez-Cajal, Manuel
A1 Ortuño, Juan
A1 Gómez-Rodríguez, Blas José
A1 Almela, Pedro
A1 Botargués, Josep María
A1 Núñez, Óscar
A1 Modolell, Inés
A1 Gómez, Judith
A1 Ruiz-Zorrilla, Rafael
A1 De la Coba, Cristóbal
A1 Huerta, Alain
A1 Iyo, Eduardo
A1 Pozzati, Liliana
A1 Antón, Rosario
A1 Barenys, Mercé
A1 Angueira, Teresa
A1 Fernández-Bermejo, Miguel
A1 Campillo, Ana
A1 Alcedo, Javier
A1 Pajares-Villaroya, Ramón
A1 Mego, Marianela
A1 Bermejo, Fernando
A1 Dominguez-Jiménez, José Luis
A1 Titó, Llúcia
A1 Fernández, Nuria
A1 Pabon-Carrasco, Manuel
A1 Cosme, Ángel
A1 Mata-Romero, Pilar
A1 Alcaide, Noelia
A1 Ariño, Inés
A1 Di Maira, Tommaso
A1 Garre, Ana
A1 Puig, Ignasi
A1 Nyssen, Olga P
A1 Megraud, Francis
A1 O'Morain, Colm
A1 Gisbert, Javier P
A1 Hp-EuReg Investigators, 
K1 Helicobacter pylori
K1 Spain
K1 first-line
K1 second-line
K1 treatment
AB The management of Helicobacter pylori infection has to rely on previous local effectiveness due to the geographical variability of antibiotic resistance. The aim of this study was to evaluate the effectiveness of first and second-line H. pylori treatment in Spain, where the empirical prescription is recommended. A multicentre prospective non-interventional registry of the clinical practice of European gastroenterologists concerning H. pylori infection (Hp-EuReg) was developed, including patients from 2013 until June 2019. Effectiveness was evaluated descriptively and through a multivariate analysis concerning age, gender, presence of ulcer, proton-pump inhibitor (PPI) dose, therapy duration and compliance. Overall, 53 Spanish hospitals were included, and 10,267 patients received a first-line therapy. The best results were obtained with the 10-day bismuth single-capsule therapy (95% cure rate by intention-to-treat) and with both the 14-day bismuth-clarithromycin quadruple (PPI-bismuth-clarithromycin-amoxicillin, 91%) and the 14-day non-bismuth quadruple concomitant (PPI-clarithromycin-amoxicillin-metronidazole, 92%) therapies. Second-line therapies were prescribed to 2448 patients, with most-effective therapies being the triple quinolone (PPI-amoxicillin-levofloxacin/moxifloxacin) and the bismuth-levofloxacin quadruple schemes (PPI-bismuth-levofloxacin-amoxicillin) prescribed for 14 days (92%, 89% and 90% effectiveness, respectively), and the bismuth single-capsule (10 days, 88.5%). Compliance, longer duration and higher acid inhibition were associated with higher effectiveness. "Optimized" H. pylori therapies achieve over 90% success in Spain.
SN 2079-6382
YR 2020
FD 2020-12-25
LK http://hdl.handle.net/10668/16872
UL http://hdl.handle.net/10668/16872
LA en
DS RISalud
RD Apr 10, 2025